Top

Published in:

Open Access 01-08-2016 | Device-Based Approaches for Hypertension (M Schlaich, Section Editor)

Device-based Therapy for Hypertension

Authors: Fu L. Ng, Manish Saxena, Felix Mahfoud, Atul Pathak, Melvin D. Lobo

Published in: Current Hypertension Reports | Issue 8/2016

Abstract

Hypertension continues to be a major contributor to global morbidity and mortality, fuelled by an abundance of patients with uncontrolled blood pressure despite the multitude of pharmacological options available. This may occur as a consequence of true resistant hypertension, through an inability to tolerate current pharmacological therapies, or non-adherence to antihypertensive medication. In recent years, there has been a rapid expansion of device-based therapies proposed as novel non-pharmacological approaches to treating resistant hypertension. In this review, we discuss seven novel devices—renal nerve denervation, baroreflex activation therapy, carotid body ablation, central iliac arteriovenous anastomosis, deep brain stimulation, median nerve stimulation, and vagal nerve stimulation. We highlight how the devices differ, the varying degrees of evidence available to date and upcoming trials. This review also considers the possible factors that may enable appropriate device selection for different hypertension phenotypes.

Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510–26. doi:10.1161/CIRCULATIONAHA.108.189141.CrossRefPubMed

Vega J, Bisognano JD. The prevalence, incidence, prognosis, and associated conditions of resistant hypertension. Semin Nephrol. 2014;34(3):247–56. doi:10.1016/j.semnephrol.2014.04.002.CrossRefPubMed

3.•

Mahfoud F, Böhm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S, et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J. 2015;36(33):2219–27. doi:10.1093/eurheartj/ehv192. Review. Proceedings from a multidisciplinary forum aimed at reviewing existing trial methodology and outcomes in the renal denervation field with recommendations for conduct of future clinical studies.CrossRefPubMed

Hameed MA, Tebbit L, Jacques N, Thomas M, Dasgupta I. Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic. J Hum Hypertens. 2016;30(2):83–9. doi:10.1038/jhh.2015.38.CrossRefPubMed

Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ. 1995;311(7000):293–5.CrossRefPubMedPubMedCentral

Strauch B, Petrák O, Zelinka T, Rosa J, Somlóová Z, Indra T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;31(12):2455–61. doi:10.1097/HJH.0b013e3283652c61.CrossRefPubMed

Patel HC, Hayward C, Vassiliou V, Patel K, Howard JP, Di Mario C. Renal denervation for the management of resistant hypertension. Integr Blood Press Control. 2015;8:57–69. doi:10.2147/IBPC.S65632.eCollection2015).CrossRefPubMedPubMedCentral

Kapil V, Jain AK, Lobo MD. Renal sympathetic denervation—a review of applications in current practice. Interv Cardiol Rev. 2014;9(1):54–61.

Esler M. The sympathetic system and hypertension. Am J Hypertens. 2000;13(6 Pt 2):99S–105S.CrossRefPubMed

10.

Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991;71(3):659–82.PubMed

11.

Steigerwald K, Titova A, Malle C, Kennerknecht E, Jilek C, Hausleiter J, et al. Morphological assessment of renal arteries after radiofrequency catheter-based sympathetic denervation in a porcine model. J Hypertens. 2012;30(11):2230–9. doi:10.1097/HJH.0b013e32835821e5.CrossRefPubMed

12.•

Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81. doi:10.1016/S0140-6736(09)60566-3. Seminal proof of principle clinical trial largely regarded to have initiated the drive towards developing device-based therapies for hypertension.CrossRefPubMed

13.

Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9. doi:10.1016/S0140-6736(10)62039-9.CrossRef

14.

Esler MD, Böhm M, Sievert H, Rump CL, Schmieder RE, Krum H, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J. 2014;35(26):1752–9. doi:10.1093/eurheartj/ehu209.CrossRefPubMed

15.

Persu A, Jin Y, Fadl Elmula FE, Renkin J, Høieggen A, Kjeldsen SE, et al. Renal denervation in treatment-resistant hypertension: a reappraisal. Curr Opin Pharmacol. 2015;21:48–52. doi:10.1016/j.coph.2014.12.013.CrossRefPubMed

16.••

Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401. doi:10.1056/NEJMoa1402670. Largest sham-controlled clinical trial for device-based therapy for hypertension.CrossRefPubMed

17.•

Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36(4):219–27. doi:10.1093/eurheartj/ehu441. A critical analysis that demonstrates how uncontrolled medication changes and the failure of interventionists to deliver per protocol renal denervation in the Symplicity HTN-3 study may have confounded the final interpretation of the neutral study findings.CrossRefPubMed

18.•

Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385(9981):1957–65. doi:10.1016/S0140-6736(14)61942-5. The most rigorously conducted randomised controlled trial of renal denervation to date.CrossRefPubMed

19.

Böhm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, et al. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension. 2015;65(4):766–74. doi:10.1161/HYPERTENSIONAHA.114.05010.CrossRefPubMed

20.

Kaiser L, Beister T, Wiese A, von Wedel J, Meincke F, Kreidel F, et al. Results of the ALSTER BP real-world registry on renal denervation employing the Symplicity system. EuroIntervention. 2014;10(1):157–65. doi:10.4244/EIJV10I1A24.CrossRefPubMed

21.

Vogel B, Kirchberger M, Zeier M, Stoll F, Meder B, Saure D, et al. Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin Res Cardiol. 2014;103(2):117–24. doi:10.1007/s00392-013-0627-5.CrossRefPubMed

22.

Sharp AS, Davies JE, Lobo MD, Bent CL, Mark PB, Burchell AE, et al. Renal artery sympathetic denervation: observations from the UK experience. Clin Res Cardiol. 2016;22.

23.

Templin C, Jaguszewski M, Ghadri JR, Sudano I, Gaehwiler R, Hellermann JP, et al. Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the Simplicity catheter system and the EnligHTN multi-electrode renal denervation catheter. Eur Heart J. 2013;34(28):2141–8. doi:10.1093/eurheartj/eht141. 2148b.CrossRefPubMedPubMedCentral

24.

Karanasos A, Van Mieghem N, Bergmann MW, Hartman E, Ligthart J, van der Heide E, et al. Multimodality intra-arterial imaging assessment of the vasculart induced by balloon-based and nonballoon-based renal denervation systems. Circ Cardiovasc Interv. 2015;8(7), e002474. doi:10.1161/CIRCINTERVENTIONS.115.002474.CrossRefPubMed

25.

Lobo MD, de Belder MA, Cleveland T, Collier D, Dasgupta I, Deanfield J, et al. Joint UK societies’ 2014 consensus statement on renal denervation for resistant hypertension. Heart. 2015;101(1):10–6. doi:10.1136/heartjnl-2014-307029.CrossRefPubMed

26.

White WB, Galis ZS, Henegar J, Kandzari DE, Victor R, Sica D, et al. Renal denervation therapy for hypertension: pathways for moving development forward. J Am Soc Hypertens. 2015;9(5):341–50. doi:10.1016/j.jash.2015.02.012.CrossRefPubMed

27.

Fischell TA, Ebner A, Gallo S, Ikeno F, Minarsch L, Vega F, et al. Transcatheter alcohol-mediated perivascular renal denervation with the peregrine system: first-in-human experience. JACC Cardiovasc Interv. 2016;9(6):589–98. doi:10.1016/j.jcin.2015.11.041.CrossRefPubMed

28.

Heuser RR, Mhatre AU, Buelna TJ, Berci WL, Hubbard BS. A novel non-vascular system to treat resistant hypertension. EuroIntervention. 2013;9(1):135–9.CrossRefPubMed

29.

Victor RG. Carotid baroreflex activation therapy for resistant hypertension. Nat Rev Cardiol. 2015;12(8):451–63. doi:10.1038/nrcardio.2015.96.CrossRefPubMed

30.

Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 2014;114(11):1804–14. doi:10.1161/CIRCRESAHA.114.302524.CrossRefPubMed

31.

Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, Mohaupt MG, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010;56(15):1254–8. doi:10.1016/j.jacc.2010.03.089.CrossRefPubMed

32.

Wustmann K, Kucera JP, Scheffers I, Mohaupt M, Kroon AA, de Leeuw PW, et al. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension. 2009;54(3):530–6. doi:10.1161/HYPERTENSIONAHA.109.134023.CrossRefPubMed

33.••

Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58(7):765–73. doi:10.1016/j.jacc.2011.06.008. Largest randomised controlled study of baroreflex activation therapy to date.CrossRefPubMed

34.

Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012;6(2):152–8. doi:10.1016/j.jash.2012.01.003.CrossRefPubMed

35.

de Leeuw PW, Alnima T, Lovett E, Sica D, Bisognano J, Haller H, et al. Bilateral or unilateral stimulation for baroreflex activation therapy. Hypertension. 2015;65(1):187–92. doi:10.1161/HYPERTENSIONAHA.114.04492.CrossRefPubMed

36.

Gassler JP, Bisognano JD. Baroreflex activation therapy in hypertension. J Hum Hypertens. 2014;28(8):469–74. doi:10.1038/jhh.2013.139.CrossRefPubMed

37.•

Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6(4):270–6. doi:10.1016/j.jash.2012.04.004. Improved safety and reduced procedure time demonstrated with second generation iteration of the baroreflex activation therapy.CrossRefPubMed

38.

Wallbach M, Lehnig LY, Schroer C, Hasenfuss G, Müller GA, Wachter R, et al. Impact of baroreflex activation therapy on renal function—a pilot study. Am J Nephrol. 2014;40(4):371–80. doi:10.1159/000368723.CrossRefPubMed

39.

Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. JACC Heart Fail. 2015;3(6):487–96. doi:10.1016/j.jchf.2015.02.006.CrossRefPubMed

40.

Paton JF, Sobotka PA, Fudim M, Engelman ZJ, Hart EC, McBryde FD, et al. The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases. Hypertension. 2013;61(1):5–13. doi:10.1161/HYPERTENSIONAHA.111.00064.CrossRefPubMed

41.

Winter B, Whipp BJ. Immediate effects of bilateral carotid body resection on total respiratory resistance and compliance in humans. Adv Exp Med Biol. 2004;551:15–21.CrossRefPubMed

42.

Ratcliffe L, Hart E, Patel NK, Szydler A, Chrostowska M, Wolf J, et al. Unilateral carotid body resection as an anti-hypertensive strategy: a proof of principle study in resistant hypertensive patients. J Hum Hypertens. 2015;29(10):625.

43.

Foran JP, Jain AK, Casserly IP, Kandzari DE, Rocha-Singh KJ, Witkowski A, et al. The ROX coupler: creation of a fixed iliac arteriovenous anastomosis for the treatment of uncontrolled systemic arterial hypertension, exploiting the physical properties of the arterial vasculature. Catheter Cardiovasc Interv. 2015;85(5):880–6.CrossRefPubMed

44.

Burchell AE, Lobo MD, Sulke N, Sobotka PA, Paton JF. Arteriovenous anastomosis: is this the way to control hypertension? Hypertension. 2014;64(1):6–12. doi:10.1161/HYPERTENSIONAHA.114.02925.CrossRefPubMed

45.

Kapil V, Sobotka PA, Saxena M, Mathur A, Knight C, Dolan E, et al. Central iliac arteriovenous anastomosis for hypertension: targeting mechanical aspects of the circulation. Curr Hypertens Rep. 2015;17(9):585.CrossRefPubMed

46.

Faul JL, Galindo J, Posadas-Valay R, Elizondo-Riojas G, Martinez A, Cooper CB. An arteriovenous fistula increases exercise capacity in patients with COPD. Chest. 2010;138(1):52–8. http://doi.org/10.1378/chest.09-2381.CrossRefPubMed

47.

Faul J et al. Creation of an iliac arteriovenous shunt lowers blood pressure in chronic obstructive pulmonary disease patients with hypertension. J Vasc Surg. 2014;59(4):1078–83.CrossRefPubMed

48.••

Lobo MD, Sobotka PA, Stanton A, Cockcroft JR, Sulke N, Dolan E, et al. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet. 2015;385(9978):1634–41. doi:10.1016/S0140-6736(14)62053-5. First randomised controlled clinical trial showing anti-hypertensive effect of a device targeting mechanical aspects of the circulation.CrossRefPubMed

49.

Brier TJ, Jain AK, Lobo MD. Central arteriovenous anastomosis for hypertension: it is not all about sympathomodulation. Future Cardiol. 2015;11(5):503–6. doi:10.2217/fca.15.34.CrossRefPubMed

50.

Lovick TA. Ventrolateral medullary lesions block the antinociceptive and cardiovascular responses elicited by stimulating the dorsal periaqueductal grey matter in rats. Pain. 1985;21(3):241–52.CrossRefPubMed

51.

Carrive P, Bandler R. Viscerotopic organization of neurons subserving hypotensive reactions within the midbrain periaqueductal grey: a correlative functional and anatomical study. Brain Res. 1991;541(2):206–15.CrossRefPubMed

52.

Patel NK, Javed S, Khan S, Papouchado M, Malizia AL, Pickering AE, et al. Deep brain stimulation relieves refractory hypertension. Neurology. 2011;76(4):405–7. doi:10.1212/WNL.0b013e3182088108.CrossRefPubMedPubMedCentral

53.

Carter HH, Dawson EA, Cable NT, Basnayake S, Aziz TZ, Green AL, et al. Deep brain stimulation of the periaqueductal grey induces vasodilation in humans. Hypertension. 2011;57(5):e24–5. doi:10.1161/HYPERTENSIONAHA.111.170183.CrossRefPubMedPubMedCentral

54.

Sverrisdóttir YB, Green AL, Aziz TZ, Bahuri NF, Hyam J, Basnayake SD, et al. Differentiated baroreflex modulation of sympathetic nerve activity during deep brain stimulation in humans. Hypertension. 2014;63(5):1000–10. doi:10.1161/HYPERTENSIONAHA.113.02970.CrossRefPubMed

55.

Li M, Tjen-A-Looi SC, Guo ZL, Longhurst JC. Electroacupuncture modulation of reflex hypertension in rats: role of cholecystokinin octapeptide. Am J Physiol Regul Integr Comp Physiol. 2013;305(4):R404–13. doi:10.1152/ajpregu.00196.2013.CrossRefPubMedPubMedCentral

56.

Li P, Tjen-A-Looi SC, Cheng L, Liu D, Painovich J, Vinjamury S, et al. Long-lasting reduction of blood pressure by electroacupuncture in patients with hypertension: randomized controlled trial. Med Acupunct. 2015;27(4):253–66.CrossRefPubMedPubMedCentral

57.

Annoni EM, Xie X, Lee SW, Libbus I, KenKnight BH, Osborn JW, et al. Intermittent electrical stimulation of the right cervical vagus nerve in salt-sensitive hypertensive rats: effects on blood pressure, arrhythmias, and ventricular electrophysiology. Physiol Rep. 2015;3(8), e12476. doi:10.14814/phy2.12476.CrossRefPubMedPubMedCentral

58.

Plachta DT, Gierthmuehlen M, Cota O, Espinosa N, Boeser F, Herrera TC, et al. Blood pressure control with selective vagal nerve stimulation and minimal side effects. J Neural Eng. 2014;11(3):036011. doi:10.1088/1741-2560/11/3/036011.CrossRefPubMed

59.

Gierthmuehlen M, Plachta DT. Effect of selective vagal nerve stimulation on blood pressure, heart rate and respiratory rate in rats under metoprolol medication. Hypertens Res. 2016;39(2):79–87. doi:10.1038/hr.2015.122.CrossRefPubMed

60.

Gierthmuehlen M, Stieglitz T, Zentner J, Plachta DT. Haemodynamic responses to selective vagal nerve stimulation under enalapril medication in rats. PLoS One. 2016;11(1), e0147045. doi:10.1371/journal.pone.0147045.CrossRefPubMedPubMedCentral

61.

Mirkovic T, Knezevic I, Radan I, Rozman J, Gersak B, Podbregar M. Frequency dependent effect of selective biphasic left vagus nerve stimulation on heart rate and arterial pressure. Signa Vitae. 2012;7(2):63–8.

62.

Esler M, Jennings G, Korner P, Willett I, Dudley F, Hasking G, et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension. 1988;11(1):3–20.CrossRefPubMed

63.•

Persu A, Jin Y, Azizi M, Baelen M, Völz S, Elvan A, et al. Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens. 2014;28(3):150–6. doi:10.1038/jhh.2013.88. An attempt to identify patient characteristics that may guide selection for renal denervation.CrossRefPubMed

64.

Ewen S, Ukena C, Linz D, Kindermann I, Cremers B, Laufs U, et al. Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. Hypertension. 2015;65(1):193–9.CrossRefPubMed

Title: Device-based Therapy for Hypertension
Authors: Fu L. Ng
Manish Saxena
Felix Mahfoud
Atul Pathak
Melvin D. Lobo
Publication date: 01-08-2016
Publisher: Springer US
Published in: Current Hypertension Reports / Issue 8/2016
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-016-0670-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2016

Device-Based Therapy for Drug-Resistant Hypertension: An Update

Baroreflex Activation Therapy in Congestive Heart Failure: Novel Findings and Future Insights

Left Ventricular Hypertrophy in Children with Hypertension: in Search of a Definition

Relationship Between Antihypertensive Medications and Cognitive Impairment: Part I. Review of Human Studies and Clinical Trials

Relationship Between Antihypertensive Medications and Cognitive Impairment: Part II. Review of Physiology and Animal Studies

Recent Updates on the Proximal Tubule Renin-Angiotensin System in Angiotensin II-Dependent Hypertension

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage